Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

Affiliations

• ¹ Division of Hematology and Medical Oncology, University of Michigan, Ann Arbor, MI, USA.
• ² Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany.
• ³ Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS, USA.
• ⁴ Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Haematology and Oncology, Klinikum Braunschweig, Braunschweig, Germany.
• ⁶ Department of Haematology and Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
• ⁷ Department of Hematology, Stanford University, Stanford, CA, USA.
• ⁸ Clinical Cooperation Unit Molecular Haematology/Oncology, German Cancer Research Centre (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
• ⁹ Department of Oncology, Jewish General Hospital, Montreal, QC, Canada.
• ¹⁰ Department of Haematology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
• ¹¹ Biostatistics, Roche Products Ltd, Welwyn Garden City, UK.
• ¹² Product Development Oncology, Genentech Inc., South San Francisco, CA, USA.